Cargando…

Influence of dose intensity and density on therapeutic and toxic effects in Hodgkin's disease.

From 1972 to 1976, 95 patients with clinical stages I-IIIA Hodgkin's disease were treated by chemotherapy with cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) before and after extended field radiotherapy. The CVPP schedule gave: (1) a constant drug dosage for each patient inde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagarde, P., Bonichon, F., Eghbali, H., de Mascarel, I., Chauvergne, J., Hoerni, B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1989
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247159/ https://www.ncbi.nlm.nih.gov/pubmed/2713252

Ejemplares similares

Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas
por: Soubeyran, P, et al.
Publicado: (1999)

Micrometastases to axillary lymph nodes from invasive lobular carcinoma of breast: detection by immunohistochemistry and prognostic significance.
por: Trojani, M., et al.
Publicado: (1987)

Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up.
por: de Mascarel, I., et al.
Publicado: (1992)

Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance.
por: Trojani, M., et al.
Publicado: (1987)

Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials.
por: Ravaud, A., et al.
Publicado: (1992)

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
por: MacGrogan, G., et al.
Publicado: (1996)

The influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in children with non-Hodgkin malignant lymphoma
por: Erculj, Nina, et al.
Publicado: (2014)

The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
por: Beard, S M, et al.
Publicado: (2000)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Late cardiopulmonary toxicity after treatment for Hodgkin's disease.
por: Allavena, C., et al.
Publicado: (1992)

Beta-Lactam Dose Optimisation in the Intensive Care Unit: Targets, Therapeutic Drug Monitoring and Toxicity
por: Legg, Amy, et al.
Publicado: (2023)

Influence of Methylenetetrahydrofolate Reductase C677T and A1298C Polymorphism on High-Dose Methotrexate-Related Toxicities in Pediatric Non-Hodgkin Lymphoma Patients
por: Lu, Suying, et al.
Publicado: (2021)

Reduced bone mineral density in men following chemotherapy for Hodgkin's disease.
por: Holmes, S. J., et al.
Publicado: (1994)

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity
por: Gibb, A, et al.
Publicado: (2013)

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017)

Hodgkins disease
por: Ferme, C, et al.
Publicado: (2001)

High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease.
por: Philip, T., et al.
Publicado: (1986)

Influence of sex differences on microRNA gene regulation in disease
por: Sharma, Salil, et al.
Publicado: (2014)

On the influence of density and morphology on the Urban Heat Island intensity
por: Li, Yunfei, et al.
Publicado: (2020)

Clustering and Hodgkin's disease.
por: Alexander, F. E.
Publicado: (1990)

Hodgkin's Disease in Children
por: Smith, I. E., et al.
Publicado: (1977)

Pulmonary toxicity induced by bleomycin in a patient with Hodgkin lymphoma
por: Oliveira, CF, et al.
Publicado: (2005)

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
por: Pei, Fajun, et al.
Publicado: (2021)

Older patients with Hodgkin Lymphoma: Walking the tightrope of efficacy and toxicity
por: Barrett, Aisling, et al.
Publicado: (2023)

Angiogenesis in Non-Hodgkin's Lymphoma: An Intercategory Comparison of Microvessel Density
por: Aggarwal, Deepti, et al.
Publicado: (2012)

Hodgkin's Disease
por: Crowther, D.
Publicado: (1981)

HODGKIN'S DISEASE
Publicado: (1973)

Hodgkin's Disease
por: Scarffe, J. H.
Publicado: (1976)

Hodgkin's Disease
Publicado: (1924)

Hodgkin's Disease
Publicado: (1974)

Hodgkin’s Disease
Publicado: (1918)

Hodgkin’s Disease
Publicado: (1914)

Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease.
por: Rubio, C., et al.
Publicado: (1997)

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life
por: Earl, H M, et al.
Publicado: (2008)

Bleomycin in Hodgkin's Lymphoma – A Boon or a Bane? – A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma
por: Udupa, Chethana Babu K, et al.
Publicado: (2019)

Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease.
por: Kaye, S. B., et al.
Publicado: (1979)

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
por: Dady, P. J., et al.
Publicado: (1982)

Hodgkin's disease mortality in Europe.
por: La Vecchia, C., et al.
Publicado: (1991)

Iron Metabolism in Hodgkin's Disease
por: Beamish, M. R., et al.
Publicado: (1972)

Does the Incidence of Treatment-Related Toxicity Plateau After Radiation Therapy: The Long-Term Impact of Integral Dose in Hodgkin's Lymphoma Survivors
por: Holtzman, Adam L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jjii4ilmpsndrevp1a6ipbdbpa